Spontaneous Remission of Metastases of Cancer of the Uterine Cervix

Gaußmann, A.; Imhoff, Detlef; Lambrecht, E; Menzel, Christoph; Mose, Stefan

doi:10.1159/000091645

Cited by 8 publications

(11 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The interval between cervical and brain lesion diagnosis was significantly shorter in the IBM group (7.5 months vs 20.05 months, IBM vs. NIBM, respectively; P = 0.006). Comparisons between IBM and NIBM are summarized in Table 1;[1-4,6-10,12-19,21-35] IBM and NIBM patient case details from previous studies are displayed in Table 2[3,5,7-10,19,20,24,26,27,30,33,35,36] and Table 3,[1,4,7,8,10,13,17,18,22,25,26,28,31,32,34,36-39,41,43] respectively.…”

Section: Resultsmentioning

confidence: 99%

Brain metastases from cervical cancer reduce longevity independent of overall tumor burden

Takayanagi

Florence

Hariri

et al. 2019

Surgical Neurology International

View full text Add to dashboard Cite

Background: Isolated brain metastasis (IBM) from cervical cancer is a very rare encounter in neurosurgery. We sought to understand how patients with isolated brain metastases differ from those with metastases in the setting of widespread disease. Methods: A systematic review was completed using PubMed and the Cochrane Library. Patients with isolated brain metastases (IBM) and non-isolated brain metastases (NIBM, or brain metastases in the setting of disseminated disease), were compared. Two-sided statistical tests were used to determine significance. Survival function was carried out using the Kaplan–Meier method. Results: A total of 89 patients, 25 with IBM and 64 with NIBM, were identified. The time interval between initial diagnosis of cervical cancer and diagnosis of brain lesion was significantly shorter in the IBM group (median 7.5 vs. 20.05 months, and IBM vs. NIBM, respectively; P = 0.006). Overall survival from initial diagnosis of cervical cancer was significantly shorter for the IBM group versus the NIBM group (7.63 vs. 26.3 months, respectively; P = 0.0005). Data demonstrate a 3.4-fold reduction of median life expectancy to 7.63 months. Survival after diagnosis of brain metastases did not differ between groups (median, IBM 7 months vs. NIBM 4 months, P = 0.08). Conclusion: Taken together, our data suggest that for cervical cancer patients with brain metastasis intracranial metastasis itself (and not overall tumor burden) represent a sentinel event in limiting longevity. While the present study is underpowered to compare treatment options directly, further work should be focused on determining the optimal treatment for these patients.

show abstract

Section: Resultsmentioning

confidence: 99%

Brain metastases from cervical cancer reduce longevity independent of overall tumor burden

Takayanagi

Florence

Hariri

et al. 2019

Surgical Neurology International

View full text Add to dashboard Cite

show abstract

“…In the early stages of cervical cancer (stage I–IIb), there is a 5-year survival of 65–80% of patients, while there is a 0% 5-year survival with disseminated metastases. [ 18 ] Cervical cancer metastasis to the brain carries a poor long-term prognosis with a reported median survival of around 2–8 months[ 2 7 9 ] and the majority of patients not surviving beyond 1 year. [ 6 ] Several of the case reports did not report overall survival of their patients.…”

Section: Discussionmentioning

confidence: 99%

“…It has been postulated that long-term survival might be due to prolonged therapeutic effects from different genes responsible for metabolizing chemotherapeutic agents, which has been seen in some patients. [ 18 ]…”

Section: Discussionmentioning

confidence: 99%

Cervical cancer metastasis to the brain: A case report and review of literature

Fetcko¹,

Gondim²,

Bonnin³

et al. 2017

Surg Neurol Int

View full text Add to dashboard Cite

Background:Intracranial metastasis from cervical cancer is a rare occurrence.Methods:In this study we describe a case of cervical cancer metastasis to the brain and perform an extensive review of literature from 1956 to 2016, to characterize clearly the clinical presentation, treatment options, molecular markers, targeted therapies, and survival of patients with this condition.Results:An elderly woman with history of cervical cancer in remission, presented 2 years later with a right temporo-parietal tumor, which was treated with surgery and subsequent stereotactic radiosurgery (SRS) to the resection cavity. She then returned 5 months later with a second solitary right lesion; she again underwent surgery and SRS to the resection cavity with no signs of recurrence 6 months later. According to the reviewed literature, the most common clinical presentation included females with median age of 48 years; presenting symptoms such as headache, weakness/hemiplegia/hemiparesis, seizure, and altered mental status (AMS)/confusion; multiple lesions mostly supratentorially located; poorly differentiated squamous cell carcinoma; and additional recurrences at other sites. The best approach to treatment is a multimodal plan, consisting of SRS or whole brain radiation therapy (WBRT) for solitary brain metastases followed by chemotherapy for systemic disease, surgery and WBRT for solitary brain lesions without systemic disease, and SRS or WBRT followed by chemotherapy for palliative care. The overall prognosis is poor with a mean and median survival time from diagnosis of brain metastasis of 7 and 4.6 months, respectively.Conclusion:Future efforts through large prospective randomized trials are warranted to better describe the clinical presentation and identify more effective treatment plans.

show abstract

“…More than half of the patients had early-stage disease at the time of the diagnosis of BMs-25.5% and 33% had stage I and II, respectively, whereas most of the patients with EC had advanced disease [53]. The histologic grade was available for 38 patients [11,14,16,21,[23][24][25]29,[31][32][33][34][35]38,39,[43][44][45]47,50,57,60,61,65], in whom 81.5% of BMs from CC have been reported to be poorly differentiated, whereas the remaining cases were to be well-or moderately differentiated. Histologic type was available in 224 patients [11,14,16,18,[21][22][23][24][25][26][28][29][30][31][32][33][34][35][36][37][38][39]…”

Section: Prevalence and Clinical Characteristicsmentioning

confidence: 99%

Brain Metastases from Uterine Cervical and Endometrial Cancer

Kato¹,

Tanase²,

Uno³

et al. 2021

Cancers

View full text Add to dashboard Cite

Reports on brain metastases (BMs) from uterine cervical carcinoma (CC) and uterine endometrial carcinoma (EC) have recently increased due to the development of massive databases and improvements in diagnostic procedures. This review separately investigates the prevalence, clinical characteristics, clinical presentation, diagnosis, treatment, and prognosis of BMs from CC and uterine endometrial carcinoma EC. For patients with CC, early-stage disease and poorly differentiated carcinoma lead to BMs, and elderly age, poor performance status, and multiple BMs are listed as poor prognostic factors. Advanced-stage disease and high-grade carcinoma are high-risk factors for BMs from EC, and multiple metastases and extracranial metastases, or unimodal therapies, are possibly factors indicating poor prognosis. There is no “most effective” therapy that has gained consensus for the treatment of BMs. Treatment decisions are based on clinical status, number of the metastases, tumor size, and metastases at distant organs. Surgical resection followed by adjuvant radiotherapy appears to be the best treatment approach to date. Stereotactic ablative radiation therapy has been increasingly associated with good outcomes in preserving cognitive functions. Despite treatment, patients died within 1 year after the BM diagnosis. BMs from uterine cancer remain quite rare, and the current evidence is limited; thus, further studies are needed.

show abstract

Spontaneous Remission of Metastases of Cancer of the Uterine Cervix

Cited by 8 publications

References 9 publications

Brain metastases from cervical cancer reduce longevity independent of overall tumor burden

Brain metastases from cervical cancer reduce longevity independent of overall tumor burden

Cervical cancer metastasis to the brain: A case report and review of literature

Brain Metastases from Uterine Cervical and Endometrial Cancer

Contact Info

Product

Resources

About